Probabilistic Approach to Generating MPOs and Its Application as a Scoring Function for CNS Drugs.

Multiparameter optimization (MPO) scoring functions are popular tools for providing guidance on how to design desired molecules in medicinal chemistry. The utility of a new probabilistic MPO (pMPO) scoring function method and its application as a scoring function for CNS drugs are described in this letter. In this new approach, a minimal number of statistically determined empirical boundaries is combined with the probability distribution of the desired molecules to define desirability functions. This approach attempts to minimize the number of parameters that define MPO scores while maintaining a high level of predictive power. Results obtained from a test-set of orally approved drugs show that the pMPO approach described here can be used to separate desired molecules from undesired ones with accuracy comparable to a Bayesian model with the advantage of better human interpretability. The application of this pMPO approach for blood-brain barrier penetrant drugs is also described.

[1]  B. Gabryel,et al.  Quantification of metformin by the HPLC method in brain regions, cerebrospinal fluid and plasma of rats treated with lipopolysaccharide , 2010, Pharmacological reports : PR.

[2]  Anna Seelig,et al.  Quantification and characterization of P-glycoprotein-substrate interactions. , 2006, Biochemistry.

[3]  G. V. Paolini,et al.  Quantifying the chemical beauty of drugs. , 2012, Nature chemistry.

[4]  P. Verhoest,et al.  Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties. , 2010, ACS chemical neuroscience.

[5]  A. Hill,et al.  Getting physical in drug discovery: a contemporary perspective on solubility and hydrophobicity. , 2010, Drug discovery today.

[6]  Li Di,et al.  Drug-like property concepts in pharmaceutical design. , 2009, Current pharmaceutical design.

[7]  Patrick E. Trapa,et al.  Strategies to minimize CNS toxicity: in vitro high-throughput assays and computational modeling , 2012, Expert opinion on drug metabolism & toxicology.

[8]  Anthony A Estrada,et al.  Chemical Biology of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors. , 2015, Journal of medicinal chemistry.

[9]  J J Baldwin,et al.  Prediction of drug absorption using multivariate statistics. , 2000, Journal of medicinal chemistry.

[10]  Z. Rankovic,et al.  CNS drug design: balancing physicochemical properties for optimal brain exposure. , 2015, Journal of medicinal chemistry.

[11]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[12]  Yaxiong Sun,et al.  De novo prediction of p-glycoprotein-mediated efflux liability for druglike compounds. , 2013, ACS medicinal chemistry letters.

[13]  D. Kyle,et al.  Cardiac effects of antimalarial treatment with halofantrine , 1993, The Lancet.